Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome

NCT00855972 · clinicaltrials.gov ↗
NA
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped The FDA IND application is paused due to additional required testing. The IRB protocol was closed prior to research starting.

Conditions

Interventions

Sponsor

Stanford University